Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSF470 + BCG + molgramostim
- Development stage
- Unknown
- Lead developer
- Laboratorio Pablo Cassará
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
CSF470 + BCG + molgramostim is an investigational therapeutic cancer vaccine regimen developed by Laboratorio Pablo Cassará for the adjuvant treatment of cutaneous melanoma. The regimen consists of **CSF-470**, an allogeneic vaccine composed of four irradiated melanoma cell lines (MEL-XY1, MEL-XY2, MEL-XY3, and MEL-XX4), administered alongside two adjuvants: **Bacillus Calmette–Guérin (BCG)** and **molgramostim** (recombinant human granulocyte-macrophage colony-stimulating factor, rHuGM-CSF). The vaccine aims to induce a potent immune response against a broad spectrum of melanoma-associated antigens presented by the irradiated tumor cells. It has been evaluated in Phase II/III clinical trials (notably the CASVAC-0401 study, NCT01729663) for patients with high-risk resected melanoma (Stages IIB-III), where it demonstrated improved distant metastasis-free survival compared to interferon-alpha 2b.
- Other names
- VACCIMELCSF-470 vaccineCSF470 vaccineCSF 470 vaccineCSF-470 plus BCG and molgramostimCSF470 plus BCG and molgramostimCSF 470 plus BCG and molgramostim
Beyond the preview
Go deeper on CSF470 + BCG + molgramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSF470 + BCG + molgramostim.